Literature DB >> 7705814

p53 protein overexpression in smooth muscle tumors of the uterus.

T H Niemann1, S S Raab, J C Lenel, J R Rodgers, R A Robinson.   

Abstract

p53 is a nuclear phosphoprotein whose overexpression may portend a poor prognosis in a variety of neoplasms. In this immunohistochemical study we examined p53 overexpression in a variety of uterine smooth muscle tumors (34 leiomyosarcomas, 18 leiomyomas, and six smooth muscle tumors of uncertain malignant potential [STUMPs]). p53 immunoreactivity was observed in none of 18 (0%) leiomyomas, one of six (17%) STUMPs, and 16 of 34 (47%) leiomyosarcomas. Reactivity was not observed in the surrounding nonneoplastic uterine smooth muscle. Strong p53 overexpression in the leiomyosarcomas was significantly associated with high grade morphology (P = .013) and a high stage at the time of presentation (P = .021). In 25 leiomyosarcoma patients with clinical follow-up, p53 overexpression was associated with shorter length of survival (P = 0.024). However, this effect was not independent of tumor stage or grade. A regression analysis showed that tumor stage was the only independent predictor of length of survival. Our study size is small, and further studies are warranted to determine the significance and replicability of these findings.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705814     DOI: 10.1016/0046-8177(95)90136-1

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.

Authors:  P Würl; H Taubert; A Meye; D Berger; C Lautenschläger; H J Holzhausen; H Schmidt; H Kalthoff; F W Rath; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

2.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Authors:  Sabrina Croce; Agnes Ribeiro; Celine Brulard; Jean-Christophe Noel; Frederic Amant; Eberhard Stoeckle; Mojgan Devouassoux-Shisheborah; Anne Floquet; Laurent Arnould; Frederic Guyon; Florence Mishellany; Delphine Garbay; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Pierre Duvillard; Philippe Terrier; Isabelle Farre; Isabelle Valo; Gaetan M MacGrogan; Frederic Chibon
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

Review 3.  Uterine myxoid leiomyosarcoma - a rare malignant tumor: the role of complex morphopathological assay. Review and case presentation.

Authors:  Anca Maria Istrate-Ofiţeru; George Lucian Zorilă; Dan Ruican; Ana Maria Petrescu; Elena Iuliana Anamaria Berbecaru; Gabriela Camelia Roşu; Răzvan Grigoraş Căpitănescu; Rodica Daniela Nagy; Liliana Cercelaru; Antonie Edu; Dominic Gabriel Iliescu; Roxana Cristina Drăguşin
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

4.  A mouse model of uterine leiomyosarcoma.

Authors:  Katerina Politi; Matthias Szabolcs; Peter Fisher; Ana Kljuic; Thomas Ludwig; Argiris Efstratiadis
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

5.  CD146 as an adverse prognostic factor in uterine sarcoma.

Authors:  Yun Zhou; He Huang; Lin-Jing Yuan; Ying Xiong; Xin Huang; Jia-Xin Lin; Min Zheng
Journal:  Eur J Med Res       Date:  2015-08-21       Impact factor: 2.175

6.  A new scoring system using multiple immunohistochemical markers for diagnosis of uterine smooth muscle tumors.

Authors:  Lea Rath-Wolfson; Yevgenia Rosenblat; Marisa Halpern; M Herbert; I Hammel; Rivka Gal; M Leabu; Rumelia Koren
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

Review 7.  Atypical uterine leiomyoma: a case report and review of the literature.

Authors:  Suzana Manxhuka-Kerliu; Irma Kerliu-Saliu; Vjollca Sahatciu-Meka; Lloreta Kerliu; Labinot Shahini
Journal:  J Med Case Rep       Date:  2016-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.